## Head and Neck Cancer Symposium Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 8 a.m.</td>
<td>Registration/Continental Breakfast</td>
</tr>
<tr>
<td>8 – 8:10 a.m.</td>
<td><strong>Welcome &amp; Opening Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Maria Kukuruzinska, PhD</td>
</tr>
<tr>
<td></td>
<td>Dean Jeffrey W. Hutter, DMD, MEd</td>
</tr>
<tr>
<td></td>
<td>Gloria Waters, PhD</td>
</tr>
<tr>
<td></td>
<td>Robert Haddad, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Targeting Pathways and Epidemiology</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Karl Kelsey, MD, MOH</td>
</tr>
<tr>
<td>8:10 – 8:30 a.m.</td>
<td><strong>Genomics of Head and Neck Squamous Cell Lung Cancers</strong></td>
</tr>
<tr>
<td></td>
<td>Peter Hammerman, MD, PhD</td>
</tr>
<tr>
<td>8:30 – 8:50 a.m.</td>
<td><strong>Gender and HPV-positive Oropharyngeal Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Maura Gillison, MD, PhD</td>
</tr>
<tr>
<td>8:50 – 9:10 a.m.</td>
<td><strong>Targeting Immune Checkpoint Pathways in HPV-associated Head and Neck Cancers</strong></td>
</tr>
<tr>
<td></td>
<td>Sara Pai, MD, PhD</td>
</tr>
<tr>
<td>9:10 – 9:30 a.m.</td>
<td><strong>Metatranscriptome of Inflammatory Diseases: Lessons Learned from Periodontitis</strong></td>
</tr>
<tr>
<td></td>
<td>Jorge Frias-Lopez, PhD</td>
</tr>
<tr>
<td>9:30 – 9:50 a.m.</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td>9:50 – 10:15 a.m.</td>
<td><strong>Coffee Break / Poster Session / Exhibits</strong></td>
</tr>
<tr>
<td></td>
<td><strong>KEYNOTE ADDRESS</strong></td>
</tr>
<tr>
<td>10:15 – 11:15 a.m.</td>
<td><strong>Targeting PI 3-Kinase for Cancer Therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Lewis Cantley, PhD</td>
</tr>
<tr>
<td></td>
<td><strong>New Technologies and Patient Care Delivery</strong></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Avrum Spira, MD, MSc</td>
</tr>
<tr>
<td>11:15 – 11:35 a.m.</td>
<td><strong>The Color of Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Gregory Grillone, MD</td>
</tr>
<tr>
<td>11:35 – 11:55 a.m.</td>
<td><strong>Advances in Radiation Therapy for Head and Neck Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>Danielle Margalit, MD, MPH</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Panel</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 11:55 a.m. - 12:15 p.m. | Expansile Nanoparticles for Imaging and Drug Delivery  
Mark Grinstaff, PhD |
| 12:15 - 12:35 p.m. | Panel Discussion                                                                |
| 12:35 - 1:30 p.m. | Lunch/Exhibits                                                                  |
| 1:30 - 1:50 p.m. | **Session 3**  
**Current and Future Therapies**  
Session Chair: Scharukh Jalisi, MD, FACS |
| 1:50 - 2:10 p.m. | Precision Medicine and HPV-Negative Head and Neck Cancer  
Barbara Burtness, MD |
| 2:10 - 2:30 p.m. | The “TORS Paradigm” for Oropharyngeal Cancer  
Bert O’Malley, Jr., MD |
| 2:30 - 2:50 p.m. | Immunotherapy Trials in Head and Neck Cancer  
Robert Haddad, MD |
| 2:50 - 3:10 p.m. | Increased Mortality in HNSCC Patients with High Intratumor Heterogeneity  
James Rocco, MD, PhD |
| 3:10 - 3:30 p.m. | Panel Discussion                                                                |
| 3:30 - 3:50 p.m. | **Session 4**  
**Clinical Problems and Challenges**  
Session Chair: Nicole Chau, MD |
| 3:50 - 4:10 p.m. | Targeting Genetic Drivers in Oral Premalignancy  
Scott Lippman, MD |
| 4:10 - 4:30 p.m. | Global Burden of Head and Neck Cancers  
Radhika Chigurupati, DMD, MS |
| 4:30 - 4:50 p.m. | Racial Disparities in Head and Neck Cancers  
Christopher Lathan, MD, MS, MPH |
| 4:50 - 5 p.m.   | Panel Discussion                                                                |
| 5 - 5:15 p.m.   | Poster and Award Presentation                                                   |
| 5:15 - 6:30 p.m. | Closing Remarks                                                                 |
|                | Reception                                                                       |
Educational Objectives
Upon completion of this activity, participants will be able to:
1. Describe current research on the etiology, pathogenesis, metastasis, and treatment of head and neck cancer;
2. Apply innovative therapeutic approaches to the treatment of head and neck cancer patients;
3. Identify the translational gap whereby advances in research are not translated into clinical applications that directly benefit patient health.

Planning Committee
(Boston University faculty unless otherwise indicated):

Maria Kukuruzinska, PhD (Co-Chair)
Professor, Molecular & Cell Biology
Associate Dean for Research
*Maria Kukuruzinska receives grant/research support from Biogen.*

Robert Haddad, MD (Co-Chair)
Disease Center Leader, Head and Neck Oncology Program
Dana-Farber Cancer Institute
*Robert Haddad receives grant/research support from Merck, BMS, Bayer, Celgene, and VentiRx, and serves as a consultant for Merck, BMS, and Bayer.*

Andrew Salama, DDS, MD, FACS (Course Director)
Assistant Professor, Oral & Maxillofacial Surgery
Director, Advanced Specialty Education Program in Oral & Maxillofacial Surgery
*Andrew Salama has nothing to disclose with regard to commercial interests.*

Douglas Faller, MD, PhD
Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology, and Laboratory Medicine
Vice-Chairman, Division of Medicine
*Douglas Faller receives grant/research support from, is a consultant for, and is a stockholder in Phoenicia Biosciences. He is also a stockholder in HemaQuest Pharmaceuticals.*

Peter Hammerman, MD, PhD
Assistant Professor, Harvard Medical School
Department of Medical Oncology, Division of Molecular and Cellular Oncology
Dana-Farber Cancer Institute
Associate Member Broad Institute of Harvard and MIT
*Peter Hammerman’s spouse is a stockholder in and employee of Pfizer. Peter Hammerman is a consultant for Clovis Oncology, Janssen, Array Biopharm, and Charles River Labs.*
Scharukh Jalisi, MD  
Director, Head and Neck Oncologic Surgery and Skullbase Surgery  
Boston Medical Center  
Associate Professor, Departments of Otolaryngology and Neurosurgery,  
Boston University School of Medicine  
*Scharukh Jalisi is the owner of Drx UC Watertown PC, an urgent care practice.*

Karl Kelsey, MD, MOH  
Professor of Epidemiology and Laboratory Medicine and Pathology  
Brown University  
Director of the Center for Environmental Health and Technology  
Brown University  
*Karl Kelsey receives grant/research support from Jansen.*

Naomi Moeller  
Boston University School of Medicine, Continuing Medical Education  
*Naomi Moeller has nothing to disclose with regard to commercial interests.*

Michael Platt, MD, MSc  
Assistant Professor of Otolaryngology  
*Michael Platt has nothing to disclose with regard to commercial interests.*

Barbara Pyke  
Associate Director of Research, Henry M. Goldman School of Dental Medicine  
Executive Director, Oral Cancer Research Initiative  
*Barbara Pyke has nothing to disclose with regard to commercial interests.*

Philip Stashenko, DMD, PhD  
President and Chief Executive Officer  
Forsyth Institute  
*Philip Stashenko has nothing to disclose with regard to commercial interests.*

Maria Trojanowska, PhD  
Professor of Medicine  
*Maria Trojanowska has nothing to disclose with regard to commercial interests.*
Faculty Disclosures

Barbara Burtness
Professor of Medicine
Clinical Research Program Leader, Head and Neck Cancers Program
Co-Director, Development Therapeutics Research Program
Yale Cancer Center
*Barbara Burtness receives grant/research support from Merck and is a consultant for Merck, VentiRx, MedImmune, Boehringer Ingelheim, and Bayer. Barbara Burtness does plan on discussing unlabeled/investigational uses of a commercial product.*

Lewis C. Cantley
Professor of Cancer Biology in Medicine
Margaret and Herman Sokol Professor in Oncology Research
Joan and Sanford I. Weill Department of Medicine
Weill Cornell College
*Lewis C. Cantley receives grant/research support from Pfizer and is a consultant for Novartis and Genentech. Lewis C. Cantley’s spouse is a stockholder of BMS and he is a stockholder. Lewis C. Cantley is a consultant, stockholder, founder, and Board of Directors member of Agios. Lewis C. Cantley does plan on discussing unlabeled/investigational uses of a commercial product.*

Nicole Chau
Physician, Dana-Farber Cancer Institute
Instructor in Medicine, Harvard Medical School
*Nicole Chau has nothing to disclose with regard to commercial interests.*

Radhika Chigurupati
Associate Professor and Director of Research, Department of Oral & Maxillofacial Surgery, Henry M. Goldman School of Dental Medicine
*Radhika Chigurupati has nothing to disclose with regard to commercial interests. Radhika Chigurupati does not plan on discussing unlabeled/investigational uses of a commercial product.*

Jorge Frias-Lopez
Associate Member of the Staff and Vice Chair, Department of Microbiology Forsyth Institute
Lecturer in Oral Medicine, Infection, and Immunity
Harvard School of Dental Medicine
*Jorge Frias-Lopez has nothing to disclose with regard to commercial interests. Jorge Frias-Lopez does not plan on discussing unlabeled/investigational uses of a commercial product.*
Maura Gillison  
Professor of Internal Medicine, Public Health and Otolaryngology  
Jeg Coughlin Chair in Cancer Research  
Ohio State University  
*Maura Gillison is a consultant for BMS. Maura Gillison does not plan on discussing unlabeled/investigational uses of a commercial product.*

Gregory Grillone  
Professor and Vice Chairman, Boston University School of Medicine  
Chair, Graduate Medical Education Committee, Boston Medical Center  
*Gregory Grillone is a consultant for Advance Medical. Gregory Grillone does not plan on discussing unlabeled/investigational uses of a commercial product.*

Mark Grinstaff  
Professor, Biomedical Engineering and Chemistry  
Boston University  
*Mark Grinstaff is a stockholder of HyperBranch Medical Technology, Acuity Bio, and Affinergy Inc. Mark Grinstaff does not plan on discussing unlabeled/investigational uses of a commercial product.*

Robert Haddad  
Disease Center Leader, Head and Neck Oncology Program  
Dana-Farber Cancer Institute  
*Robert Haddad receives grant/research support from Merck, BMS, Bayer, Celgene, and VentiRx, and serves as a consultant for Merck, BMS, and Bayer. Robert Haddad does not plan on discussing unlabeled/investigational uses of a commercial product.*

Peter Hammerman  
Assistant Professor, Harvard Medical School  
Department of Medical Oncology, Division of Molecular and Cellular Oncology  
Dana-Farber Cancer Institute  
Associate Member Broad Institute of Harvard and MIT  
*Peter Hammerman’s spouse is a stockholder and employee of Pfizer. Peter Hammerman is a consultant for Clovis Oncology, Janssen, Array Biopharm, and Charles River Labs. Peter Hammerman does not plan on discussing unlabeled/investigational uses of a commercial product.*

Scharukh Jalisi  
Director, Head and Neck Oncologic Surgery and Skullbase Surgery  
Boston Medical Center  
Associate Professor, Departments of Otolaryngology and Neurosurgery  
Boston University School of Medicine  
*Scharukh Jalisi is the owner of Drx UC Watertown PC, an urgent care practice.*
Karl Kelsey, MD, MOH  
Professor of Epidemiology and Laboratory Medicine and Pathology  
Brown University  
Director of the Center for Environmental Health and Technology  
Brown University  
Karl Kelsey receives grant/research support from Jansen.

Christopher Lathan  
Faculty Director for Cancer Care Equity, Dana-Farber Cancer Institute  
Physician, Dana-Farber Cancer Institute  
Assistant Professor of Medicine, Harvard Medical School  
Christopher Lathan has nothing to disclose with regard to commercial interests.  
Christopher Lathan does not plan on discussing unlabeled/investigational uses of a commercial product.

Scott Lippman  
Professor of Medicine  
Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care  
Chugai Pharmaceutical Chair in Cancer  
UC San Diego Moores Cancer Center  
Scott Lippman has nothing to disclose with regard to commercial interests. Scott Lippman does plan on discussing unlabeled/investigational uses of a commercial product.

Danielle Margalit  
Physician, Dana-Farber Cancer Institute  
Assistant Professor of Radiation Oncology, Harvard Medical School  
Danielle Margalit has nothing to disclose with regard to commercial interests. Danielle Margalit does not plan on discussing unlabeled/investigational uses of a commercial product.

Bert O’Malley  
Associate Vice President, Physician Network Development  
Chair, Department of Otorhinolaryngology  
Co-Director, Head and Neck Cancer Center  
Director, Penn Otolaryngology Residency Program  
Gabriel Tucker Professor of Otorhinolaryngology  
Professor of Otorhinolaryngology in Neurosurgery  
Professor of Radiation Oncology  
University of Pennsylvania  
Bert O’Malley receives royalties from the University of Pennsylvania through Olympus.  
Bert O’Malley does not plan on discussing unlabeled/investigational uses of a commercial product.
Sara Pai  
Member of the Faculty of Surgery, Massachusetts General Hospital  
*Sara Pai receives grant/research support and is a consultant for Astrazeneca, AbbVie, and OncoSec. Sara Pai receives grant/research support and does educational talks for Merck. Sara Pai does not plan on discussing unlabeled/investigational uses of a commercial product.*

James Rocco  
Professor and John and Mary Alford Chair of Head and Neck Surgery  
The Ohio State University Wexner Medical Center  
Director, Division of Head and Neck Oncologic Surgery  
Medical Director, Head and Neck Service Line  
James Cancer Hospital/Solove Research Institute  
Co-Director, Head and Neck Disease Specific Research Group  
Ohio State University  
*James Rocco has nothing to disclose with regard to commercial interests. James Rocco does not plan on discussing unlabeled/investigational uses of a commercial product.*

Avrum Spira  
Professor of Medicine, Pathology & Laboratory Medicine, and Bioinformatics  
Chief, Division of Computational Biomedicine, Boston University School of Medicine  
Director, Translational Bioinformatics Program  
Clinical and Translational Science Institute  
*Avrum Spira is a consultant for and stockholder of Veracyte Inc.*

Carter Van Waes  
Chief, Head and Neck Surgery Branch  
Clinical Director  
National Institute on Deafness and Other Communication Disorders, National Institutes of Health  
*Carter Van Waes investigates research drugs for Pfizer and Tetralogic. Carter Van Waes does not plan on discussing unlabeled/investigational uses of a commercial product.*
Faculty Disclosure Policy
Boston University School of Medicine asks all individuals involved in the
development and presentation of Continuing Medical Education (CME) activities
to disclose all relationships with commercial interests. This information is disclosed
to CME activity participants. Boston University School of Medicine has procedures
to resolve any apparent conflicts of interest. In addition, faculty members are asked
to disclose when any unapproved use of pharmaceuticals and devices is being
discussed.

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION
WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR
PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR
QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES
FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF
BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER
REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN
NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY
DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT
SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR
PROFESSIONAL CARE.

References

Sano D, Myers JN. (2009) Xenograft models of head and neck cancers. Head Neck
Oncol. 2009 Aug 13; 1:32.

Boyko JA, Lavis JN, Abelson J, Dobbins M, Carter N., Deliberative dialogues as a
mechanism for knowledge translation and exchange in health systems decision-

National Institute of Dental & Craniofacial Research
Funding for this conference was made possible in part by R13DE025552 from
the National Institute of Dental & Craniofacial Research. The views expressed in
written conference materials or publications and by speakers and moderators do
not necessarily reflect the official policies of the Department of Health and Human
Services; nor does mention of trade names, commercial practices, or organizations
imply endorsement by the U.S. Government.
Adenoid Cystic Carcinoma Research Foundation
ACC RF supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease. The foundation expects to achieve its mission by developing a community of interested researchers, helping devise a directed research agenda, and mobilizing patients in support of research.

Boston University Henry M. Goldman School of Dental Medicine
The School of Dental Medicine maintains research momentum against a background of rapidly evolving scientific discoveries and technological advances by promoting and supporting diverse research programs relevant to oral health. Research spans areas of basic, clinical, public health and translational sciences. The School continually expands its research agenda by providing faculty and students with collaborative interdisciplinary research opportunities. Investigators are dedicated to scientific discovery and its translation to cures for human disease, as well as to improving quality of life and eliminating health disparities.

Center for Future Technologies in Cancer Care
CFTCC is focused on the identification, prototyping and early clinical assessment of innovative point of care technologies for the treatment, screening, diagnosis and monitoring of cancers. We aid investigators in the assessment of early stage technology in terms of clinical needs, market demands, prototyping and setting appropriateness.

Clinical and Translational Science Institute
The Boston University CTSI, funded by the NIH under NCATS, aims to speed discovery and advance science aimed at improving health. The program encourages collaborative teams of diverse investigators to tackle complex health and research challenges and then find ways to turn their discoveries into practical solutions for patients.

Evans Center for Interdisciplinary Biomedical Research
The goal of the Evans Center, directed by Dr. Katya Ravid, is to promote growth and discovery in emerging interdisciplinary biomedical research and educational areas by providing faculty affiliated with the Department of Medicine and with various schools, departments and centers at Boston University a dynamic, interdisciplinary organizational structure, which allows investigators with different areas of expertise to collectively address mechanisms of disease, and to facilitate new training opportunities.
National Institute of Dental and Craniofacial Research
The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to improve dental, oral, and craniofacial health through research, research training, and the dissemination of health information.

Oral Cancer Foundation
The Oral Cancer Foundation, an IRS 501c3 non-profit charity provides vetted disease and treatment information, disease advocacy, patient support, and financial sponsorship of peer-reviewed research. Through public and professional education and outreach, early detection initiatives, OCF efforts reduce physical and emotional suffering, and ultimately deaths from this disease.
www.oralcancer.org

Commercial Sponsors

KLS Martin
KLS Martin is a company dedicated to providing innovative medical devices and power systems for craniomaxillofacial surgery. The company’s rich history began with surgical instrument production in Tuttlingen, Germany in 1896 and continued with miniplate production in 1975. KLS Martin has advanced the capabilities of distraction osteogenesis, and revolutionized resorbable fixation with the SonicWeld Rx system.

Vigilant Biosciences
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate, and cost-effective, empowering healthcare practitioners to easily assess the risk of oral cancer early and improve outcomes through earlier intervention.

Educational Grants

This activity is provided in part by educational grants from:
AstraZeneca
DePuy Synthes
Medtronic

Exhibitors

This activity is provided in part by exhibits from:
KLS Martin
Medtronic
Vigilant Biosciences
GOLD SPONSOR

KLS Martin

The KLS Martin Group is a global family of companies dedicated to designing, manufacturing, and marketing a wide range of craniomaxillofacial surgical products. Our manufacturing and international sales and marketing facility is located in southern Germany between the Black Forest and the Lake of Constance. The world’s finest surgical instruments have been produced in our facilities for over 100 years. KLS Martin Group factories are equipped with the most advanced computer-aided design and manufacturing equipment available. Much of the machinery used to produce our craniomaxillofacial plating products has been custom made to our specifications and is one of the primary reasons for our unique quality. The use of our state of the art technology by skilled craftsmen with generations of surgical instrument making experience has resulted in the finest array of craniomaxillofacial products in the industry.

In 1993, the formation of the KLS Martin partnership in North America extended the global commitment to the craniomaxillofacial surgical specialties. Our mission is to continue to be a company responsive to the development of innovative products for our customers. We have a team of professional consultants dedicated to your surgical specialty.

KLS Martin L.P. is proud to support the Oral Cancer Research Initiative (OCRI) at the 2015 conference as it expedites and advances translation of research toward diagnosis, prevention, treatment and cure of oral cancer.

SILVER SPONSOR

Vigilant Biosciences

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Vigilant’s products are based on patented technology that detects specific protein markers known to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention.

Vigilant Biosciences is proud to support the Oral Cancer Research Initiative (OCRI) at the 2015 conference as it expedites and advances translation of research toward diagnosis, prevention, treatment and cure of oral cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine, Boston University Henry M. Goldman School of Dental Medicine and the Dana-Farber Cancer Institute. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Symposium is provided by Boston University School of Medicine.

The meeting is provided in collaboration with the Boston University Henry M. Goldman School of Dental Medicine and the Dana-Farber Cancer Institute.